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A number of new cephalosporins which have an extended broad-spectrum antibacterial activity for the therapeutic use in respiratory and urinary-tract infections have been launched or are currently under clinical development. However, few cephalosporins have significant activity against Pseudomonas aeruginosa, which causes refractory infections in immunocompromised patients. To discover antipseudomonal cephalosporins with a broad-spectrum antibacterial activity, several catecholsubstituted cephalosporins have been synthesized (1-3, 6, 7, 10-13, 16, 21) . It has been reported that the introduction of a catechol group on ␤-lactam structures enhanced the capability of drugs to penetrate into gram-negative bacteria, especially P. aeruginosa, by utilizing the tonB-dependent iron transport system (5, 20) . In contrast to its improved activities against gramnegative organisms, most of the already known catecholic cephalosporins have poor antibacterial activities against grampositive bacteria.
LB10522 {7-[(Z)-2-(2-aminothiazol-4-yl)-2-(S)-(a-carboxyl-3,4-dihydroxybenzyloxyimino)acetamide]-3-[(E)-3-(4-
-1-pyrimidino)-1-propen-1-yl]-3-cephem-4-carboxylate} is a parenteral cephalosporin that has a catechol moiety at the 7-oxime side chain (Fig. 1) . This compound exhibited a well-balanced and broad-spectrum antibacterial activity against gram-positive and gram-negative bacteria. In particular, LB10522 showed potent activities against Staphylococcus aureus and P. aeruginosa.
In this paper, we describe in vitro and in vivo activities of LB10522 compared with those of cefpirome, ceftazidime, ceftriaxone, and cefoperazone. In addition, the stabilities to various ␤-lactamases and a time-kill study are reported.
(This work was presented in part at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy [9, 17] .)
MATERIALS AND METHODS
Antimicrobial agents. LB10522 and cefpirome were synthesized at Biotech Research Institute, LG Chemical Ltd. Commercially available antibiotics were obtained as reference compounds: ceftazidime (Glaxo), cefotaxime (Hoechst), ceftriaxone (Sigma), cefoperazone (Sigma), cephaloridine (Sigma), cefoxitin (Sigma), and cefsulodine (Sigma).
Test organisms. The bacterial strains used in this study were originally isolated from human clinical specimens. These were collected at several hospitals in Korea between 1991 and 1994. All isolates were stored frozen at Ϫ70ЊC.
Susceptibility tests. MICs of LB10522 against clinical isolates and ␤-lactamase-producing resistant strains were determined by the agar dilution method described by the National Committee for Clinical Laboratory Standards (15 Time-kill study. Test organisms incubated in MH broth for 18 h at 35ЊC were diluted with fresh broth to approximately 10 5 CFU/ml, and the diluted cultures were preincubated for 2 h. Each drug was added to the cultures at the concentrations of 1/4, 1/2, 1, 2, and 4 times the MIC. Aliquots (100 l) of the cultures were removed at 0, 2, 4, 6, and 24 h of incubation, and several dilutions were prepared in saline as needed. Drug carryover effects were reduced by 100-fold dilution of the sample with agar. The number of viable cells was determined on a drug-free MH agar plate. MBC was determined also by subculturing 100 l of culture broth onto an antibiotic-free MH agar plate and defined as the lowest concentration which induced a Ͼ99.9% reduction in CFU after 18 h of incubation at 35ЊC (14) .
In vivo activity. In vivo activity of LB10522 was determined against systemic infections in mice. Test organisms for infection were cultured on tryptic soy agar medium (Difco) at 35ЊC for 18 h and were suspended in gastric mucin (Difco). Male ICR mice (Biotech Research Institute) weighing 19 to 21 g in four groups of six mice were infected intraperitoneally with 0.5 ml of a bacterial suspension corresponding to an inoculum range of 5 to 10 times the minimal lethal dose of bacteria. Four dose levels were used for each antibiotic, depending on in vitro antimicrobial activity of the compounds. Mice were subcutaneously injected twice, at 1 and 4 h postinfection, with various dose regimens of antibiotics. Mortality was recorded for 7 days, and the median effective dose needed to protect 50% of mice (ED 50 ) was calculated by the method of Bliss (4). All untreated mice died within 2 days after infection.
Stability to ␤-lactamases. To determine ␤-lactamase stability, cell-free sonic extracts of ␤-lactamase-producing strains were prepared from mid-exponentialphase cultures in tryptone soy broth. The rates of hydrolysis of the drugs by several ␤-lactamases were assayed in a temperature-controlled UV spectrophotometer (Shimadzu UV-2000) at 35ЊC. All antibiotic solutions were prepared immediately before use in 50 mM sodium phosphate buffer, and the reaction was monitored at a wavelength which gave the maximum change in absorbance after hydrolysis. The stabilities of the drugs to hydrolysis by ␤-lactamases were expressed as the rate of hydrolysis relative to that of cephaloridine, which was assigned a value of 100%. The kinetic parameters, such as K m , K i , and V max , of the compounds for TEM-9 ␤-lactamase were also determined from hydrolytic rates at various substrate concentrations by use of a Lineweaver-Burk plot. V max /K m can be taken as a measure of efficiency of hydrolysis, as defined by Pollock (18) .
Induction of ␤-lactamase. An overnight culture of Enterobacter cloacae 1194E was diluted 20-fold into 10 ml of fresh brain heart infusion broth (Difco) and incubated with shaking at 35ЊC. After 2.5 h of incubation (mid-log phase), test compounds were added as inducers. Incubation was continued for 2 h, and the cells were harvested and washed twice with 50 mM phosphate buffer (pH 7.0). The cells were suspended in the same buffer and disrupted with sonicator in ice water. Cell debris and unbroken cells were removed by centrifugation, and the resulting supernatant fluid was used as a crude enzyme. ␤-Lactamase activity was determined with 100 M cephaloridine as the substrate (19) . The protein concentration was estimated by the method of Bradford (4a) with bovine serum albumin as the standard.
RESULTS
In vitro antibacterial activity. In vitro activities of LB10522 against 1,243 clinical isolates were compared with those of cefpirome, ceftazidime, ceftriaxone, and cefoperazone. Table 1 summarized MIC ranges and MICs for 50 and 90% of the strains tested (MIC 50 s and MIC 90 s, respectively). LB10522 showed an extended broad spectrum of antibacterial activity against gram-positive and gram-negative bacteria including non-glucose-fermenting rods, P. aeruginosa.
Against methicillin-susceptible strains of Staphylococcus aureus, LB10522 with a MIC 90 of 0.5 g/ml was fourfold more active than cefpirome. LB10522 was also more active than the other cephalosporins tested against methicillin-susceptible Staphylococcus epidermidis, Streptococcus pyogenes, and Enterococcus faecalis. However, methicillin-resistant strains of Staphylococcus aureus and Staphylococcus epidermidis (MRSE) were highly resistant to all cephalosporins tested.
LB10522 was active against most members of the family Enterobacteriaceae, 90% of which were inhibited at the concentration of less than 0.5 g/ml, except for Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii, Klebsiella pneumoniae, Serratia marcescens, and Morganella morganii. Against E. coli and Proteus mirabilis, MIC 90 s of LB10522 were 0.25 and 0.13 g/ml, respectively, and were equal to those of cefpirome. Against Proteus vulgaris, LB10522 with a MIC 90 of 0.5 g/ml was twofold less active than cefpirome. LB10522 inhibited 90% of isolates in Klebsiella oxytoca and Salmonella spp. at the concentration of 0.13 g/ml and was comparable to cefpirome in activity. However, Enterobacter cloacae was not well inhibited by the compounds tested. MIC 90 s of LB10522, cefpirome, and ceftazidime against this species were 32, 16, and 64 g/ml, respectively, but more than 50% of the strains were susceptible to LB10522 and cefpirome. Against Enterobacter aerogenes, Citrobacter freundii, and Klebsiella pneu-moniae, MIC 90 of LB10522 was 4 g/ml. LB10522 was as active as cefpirome but 4-to 32-fold more active than ceftazidime, ceftriaxone, and cefoperazone. LB10522 had activity similar to that of cefpirome but was more active than the other cephalosporins against Serratia marcescens and M. morganii. The characteristic feature of LB10522 was its good activity against P. aeruginosa. MIC 90 of LB10522 against P. aeruginosa was 2 g/ml, and its activity was 16-to 64-fold better than those of the reference compounds. Against Acinetobacter calcoaceticus, the activity of LB10522 was similar to that of cefpirome but more potent than that of the other cephalosporins. Stenotrophomonas maltophilia and Flavobacterium spp. were highly resistant to all compounds tested.
Time-kill study. The bactericidal activity of LB10522 compared with that of cefpirome is shown in Fig. 2 . LB10522, at concentrations of two and four times the MIC, had a rapid bactericidal activity against Staphylococcus aureus ATCC 6538p, E. coli 851E, and P. aeruginosa 1912E, and regrowth after 24-h incubation was not detected. This bactericidal effect was comparable to that of cefpirome. MBCs of LB10522 in MH broth were two to four times as high as MICs for all test strains.
In vivo activity in mice. The protective effects of LB10522 against systemic infections induced by nine different pathogenic strains are compared with those of cefpirome and ceftazidime in Table 2 . LB10522 exhibited the most potent protective effects against systemic bacterial infections except for Streptococcus pyogenes and M. morganii. Against Staphylococcus aureus giorgio infection, the ED 50 s of LB10522, cefpirome, and ceftazidime were 0.7, 0.8, and 12.1 mg/kg of body weight, respectively. Against Streptococcus pneumoniae III infection, LB10522 with an ED 50 of 2.39 mg/kg was comparable to cefpirome (4.16 mg/kg) but 16-fold more active than ceftazidime (39.1 mg/kg). The ED 50 s of LB10522, cefpirome, and ceftazidime against Streptococcus pyogenes 77A infection were 1.47, 0.18, and 9.65 mg/kg, respectively. LB10522 was less active than cefpirome, but it was more potent than ceftazidime. Against P. aeruginosa 1912E infection, LB10522 with an ED 50 of 2.69 mg/kg was more active than cefpirome (10.9 mg/kg) and ceftazidime (8.42 mg/kg). Against E. coli 851E, the ED 50 of LB10522 was 0.82 mg/kg, which was about half of those of cefpirome and ceftazidime. The ED 50 s of LB10522, cefpirome, and ceftazidime against Proteus mirabilis 1315E were 1.43, 6.51, and 2.22 mg/kg, respectively. LB10522 (ED 50 , 0.16 mg/kg) was also more active than cefpirome (0.62 mg/kg) and ceftazidime (2.84 mg/kg) against Serratia marcescens 1826E infection. Against M. morganii 1375E, the ED 50 s of LB10522, cefpirome, and ceftazidime were 0.54, 0.35, and 4.00 mg/kg, respectively. LB10522 was slightly less active than cefpirome but eight times more active than ceftazidime. LB10522 with an ED 50 of 0.12 mg/kg was more active than cefpirome (0.97 mg/kg) and ceftazidime (1.43 mg/kg) against A. calcoaceticus Ac-54 infection. These results showed that LB10522 had more potent in vivo activities than those expected from in vitro activities.
Stability to ␤-lactamases. The susceptibility of LB10522 to enzymatic hydrolysis was evaluated by measuring the relative hydrolysis rates for several types of ␤-lactamases. Table 3 shows that LB10522 was more stable than the reference compounds to hydrolysis by ␤-lactamases. The enzyme kinetic pa- The enzyme activity was determined by the spectrophotometric assay at 35ЊC and is expressed relative to the rate for cephaloridine, which was assigned a value of 100.
c NA, the rate of hydrolysis was too slow to determine. rameters of the drugs for TEM-9 ␤-lactamase were determined by measuring K i , V max , and K m ( Table 4 ). The physiological efficiency (V max /K m ) of LB10522 was similar to those of cefpirome and cefotaxime. In vitro antibacterial activities of LB10522 against representative ␤-lactamase-producing bacterial strains are compared with those of the reference cephalosporins in Table 5 . LB10522 had potent antibacterial activity against the ␤-lactamase-producing resistant strains. High stability of LB10522 to various ␤-lactamases is likely to be the major reason for its excellent activity against resistant strains.
Induction of ␤-lactamase. Figure 3 shows the activities of the enzyme induced in Enterobacter cloacae 1194E by LB10522 and reference compounds. Although most of the test compounds induced ␤-lactamase even at low concentrations below their MICs, LB10522 and ceftazidime did not induce ␤-lactamase at high concentrations. The induction pattern was dose dependent for the compounds. LB10522 was the weakest inducer among the compounds tested. FIG. 3 . Induction of ␤-lactamase in Enterobacter cloacae 1194E by LB10522 and other cephalosporins. ␤-Lactamase activity was determined by the spectrophotometric method measuring the decrease in absorbance (⌬Abs) in a temperature-controlled spectrophotometer at 30ЊC. Cephaloridine (100 M) was used as a substrate. s, cefotoxin; {, cephaloridine; å, cefpirome; ϫ, cefsulodine; ᮀ, ceftriaxone; E, ceftazidime; F, LB10522. 
